Updated data and regulatory step
Larimar Therapeutics reported updated long-term results from an open-label study and said it has filed the first module of a rolling Biologics License Application with the U.S. Food and Drug Administration for nomlabofusp, its lead candidate for Friedreich's ataxia. The company disclosed these items during a pre-market investor webcast, and the regulatory submission is part of an accelerated approval pathway.
Market reaction
The market reaction was pronounced: the stock declined nearly 19.6% in pre-open trading. That drop followed the webcast and the filing confirmation, reflecting what market participants often call a "sell the news" response when previously expected catalysts are confirmed rather than exceed expectations.
Safety findings weigh on sentiment
A central investor concern highlighted in the update is the drug's safety profile. The company disclosed that 10 of 43 patients in the open-label study experienced anaphylaxis. Importantly, 9 of those 10 anaphylactic events occurred in patients who had prior exposure to nomlabofusp in an earlier study. While Larimar stated that long-term dosing was generally well tolerated aside from these events, the recurrence of anaphylaxis remains a material overhang for market confidence.
Regulatory timeline and filing completeness
Although the FDA previously indicated in Type B pre-BLA meeting minutes that available data appeared capable of supporting a BLA submission and review, Larimar's current filing is partial. The company confirmed that the critical chemistry, manufacturing, and controls module will not be submitted until the second half of 2026. Because that module is outstanding, the agency cannot commence a full review until the filing is complete, extending regulatory timeline risk toward the company's stated goal of a mid-2027 U.S. launch.
Wider market context
The broader equity market offered little support for Larimar's shares on the day. Major U.S. indexes were essentially flat to modestly lower, with the S&P 500 off 0.05% and the NASDAQ down 0.2%, leaving the decline driven by company-specific factors rather than a sector-wide move. Larimar's peer group in rare-disease biotechnology was not cited as a driver of the selloff; the catalyst was centered on Larimar's own data and regulatory progress.
Implications for valuation and near-term outlook
Taken together, the combination of a partial BLA filing, the persistent anaphylaxis signal observed in the open-label dataset, and the market dynamic of pre-pricing a catalyst followed by selling on confirmation helped push the stock toward the low end of its 52-week range, between $2.715 and $6.42. Investors will now be watching for the CMC submission timeline and any further safety data that could influence regulatory review and commercial prospects.
Note on limitations
The company provided the updated results and regulatory status during its webcast. Where information in the update was limited, this report reflects those limits rather than expanding beyond the disclosed items.